- Envoy Medical, Inc. (NASDAQ: COCH) has received a **positive listing determination** from the Nasdaq Hearings Panel, granting the company's request for **continued listing** on the Nasdaq Stock Market.  **[1840877_0001213900-25-102828_ea026270001ex99-1_envoy.htm:0]** 
- The company has been granted an extension until **February 23, 2026**, to demonstrate full compliance with Nasdaq Listing Rule 5550(b)(2), which pertains to the **$35 million market value of listed securities** requirement.  **[1840877_0001213900-25-102828_ea026270001ex99-1_envoy.htm:0]** **[1840877_0001213900-25-102828_ea0262700-8k_envoy.htm:1]** 
- The Panel's decision considered several key developments, including Envoy Medical's recent **equity capital raises**, **debt extinguishment**, and the **FDA's approval** for the final stage of the Acclaim® cochlear implant clinical trial.  **[1840877_0001213900-25-102828_ea026270001ex99-1_envoy.htm:0]**

Envoy Medical Receives Nasdaq Listing Extension

- Envoy Medical, Inc. (NASDAQ: COCH) announced a registered direct offering of **3,007,524 shares** of Class A common stock at a purchase price of **$1.33 per share**, along with a concurrent private placement of unregistered warrants to purchase up to **9,022,572 shares** of Class A common stock, also at an exercise price of **$1.33 per share**.  **[1840877_0001213900-25-097600_ea026075301ex99-1_envoy.htm:0]** **[1840877_0001213900-25-097600_ea0260753-8k_envoy.htm:1]** 
- The offering is expected to generate **$4.0 million** in gross proceeds, with a potential for an additional **$12 million** if the unregistered warrants are fully exercised.  **[1840877_0001213900-25-097600_ea026075301ex99-1_envoy.htm:0]** **[1840877_0001213900-25-097600_ea0260753-8k_envoy.htm:2]** 
- The company intends to use the net proceeds from the offering for **working capital and other general corporate purposes**.  **[1840877_0001213900-25-097600_ea026075301ex99-1_envoy.htm:0]** **[1840877_0001213900-25-097600_ea0260753-8k_envoy.htm:2]** 
- The offering is anticipated to close on or about **October 9, 2025**, with H.C. Wainwright & Co. acting as the exclusive placement agent.  **[1840877_0001213900-25-097600_ea026075301ex99-1_envoy.htm:0]** **[1840877_0001213900-25-097600_ea0260753-8k_envoy.htm:2]**

Envoy Medical Announces Up to $16 Million Registered Direct Offering

- Envoy Medical, Inc. received **FDA approval** to advance its pivotal clinical trial for the fully implanted Acclaim® cochlear implant to the final stage, based on **promising three-month data** from the first 10 patients.  **[1840877_0001213900-25-096845_ea026049401ex99-1_envoy.htm:0]** **[1840877_0001213900-25-096845_ea0260494-8k_envoy.htm:1]** 
- This approval is expected to **shorten the estimated timeline by three to six months** and **reduce the anticipated capital need by $10-$15 million**.  **[1840877_0001213900-25-096845_ea026049401ex99-1_envoy.htm:0]** 
- The company expects to complete **full enrollment by early 2026** for the final stage of the trial, which will include an additional 46 participants.  **[1840877_0001213900-25-096845_ea026049401ex99-1_envoy.htm:0]**

Envoy Medical Receives FDA Approval for Acclaim Cochlear Implant Trial Expansion

- **Envoy Medical Inc.** (NASDAQ: COCH) announced a **registered direct offering** of **1,908,402 shares of Class A common stock** at a purchase price of **$1.31 per share**, expected to generate approximately **$2.5 million** in gross proceeds.  **[1840877_0001213900-25-090373_ea025837101ex99-1_envoy.htm:0]** **[1840877_0001213900-25-090373_ea0258371-8k_envoy.htm:1]** 
- In a concurrent private placement, the company will issue **unregistered warrants** to purchase up to **5,725,206 shares of Class A common stock** with an exercise price of **$1.31 per share**.  **[1840877_0001213900-25-090373_ea025837101ex99-1_envoy.htm:0]** **[1840877_0001213900-25-090373_ea0258371-8k_envoy.htm:1]** 
- If these unregistered warrants are fully exercised, they could provide an **additional $7.5 million** in gross proceeds.  **[1840877_0001213900-25-090373_ea025837101ex99-1_envoy.htm:0]** **[1840877_0001213900-25-090373_ea0258371-8k_envoy.htm:2]** 
- The offering is priced **at-the-market under Nasdaq rules** and is anticipated to close on or about **September 23, 2025**.  **[1840877_0001213900-25-090373_ea025837101ex99-1_envoy.htm:0]** **[1840877_0001213900-25-090373_ea0258371-8k_envoy.htm:2]** 
- The net proceeds from the offering are intended for **working capital and other general corporate purposes**.  **[1840877_0001213900-25-090373_ea025837101ex99-1_envoy.htm:0]** **[1840877_0001213900-25-090373_ea0258371-8k_envoy.htm:2]** **[1840877_0001213900-25-090373_ea025837101ex10-1_envoy.htm:34]**

Envoy Medical Announces Registered Direct Offering and Concurrent Private Placement

- On **August 25, 2025**, Envoy Medical, Inc. **extinguished over $32 million in debt** (including principal and accrued interest) owed to GAT Funding, LLC, in exchange for a **cash payment of $100,000**.  **[1840877_0001213900-25-080530_ea025459001ex99-1_envoy.htm:0]** **[1840877_0001213900-25-080530_ea0254590-8k_envoy.htm:1]** 
- The extinguished debt comprised promissory notes from February 2024, August 2024, and March 2025, with a total outstanding principal balance of **$30,800,000** and accrued interest of **$1,211,552** as of the effective date.  **[1840877_0001213900-25-080530_ea025459001ex10-1_envoy.htm:0]** 
- This action is expected to **strengthen the company's balance sheet** and **simplify its capital structure** by eliminating all term loan obligations without equity conversion.  **[1840877_0001213900-25-080530_ea025459001ex99-1_envoy.htm:0]** 
- Concurrently, **Glen A. Taylor**, owner of GAT Funding, LLC and the company's largest stockholder, **retired from Envoy Medical's Board of Directors** effective August 25, 2025.  **[1840877_0001213900-25-080530_ea025459001ex99-1_envoy.htm:0]** **[1840877_0001213900-25-080530_ea0254590-8k_envoy.htm:1]**

Envoy Medical (COCH)